Magnetic nanoparticles for sample separation

Uniformly coated magnetic nanoparticles with controlled silica thickness and aggregation form stable clusters, addressing surface unevenness and aggregation issues, enabling efficient nucleic acid purification and automated workflows.

KR103046659B1Active Publication Date: 2026-11-11AGILENT TECHNOLOGIES INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
KR1020247013893
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-09-30
Filing Date
2022-09-30
Publication Date
2026-11-11
Estimated Expiration
2042-09-30

AI Technical Summary

Technical Problem

Existing silica-coated magnetic nanoparticles for nucleic acid purification suffer from uneven silica surfaces and aggregation issues, leading to inefficient and laborious sample preparation processes, particularly in nucleic acid diagnostics and sequencing, which are costly and require skilled personnel.

Method used

A method for producing uniformly coated magnetic nanoparticles with a controlled silica layer thickness and aggregation period to form stable clusters, enhancing nucleic acid binding and purification efficiency.

Benefits of technology

The method provides stable, efficient, and rapid nucleic acid purification, enabling automated workflows and reducing labor and costs in diagnostics and sequencing, suitable for various sample types including FFPE samples.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024045525113-PCT00015_ABST
    Figure 112024045525113-PCT00015_ABST
Patent Text Reader

Abstract

The present invention relates to a method for manufacturing and using silica-coated magnetic nanoparticles, comprising silica-coated magnetic nanoparticles having a greater ability to maintain a dispersed state, and incubating an aqueous dispersion of the newly manufactured particles at room temperature for a certain period of time to produce silica-coated magnetic nanoparticle clusters, wherein the generated clusters have an optimal size for viral RNA extraction from human clinical samples. The magnetic nanoparticles comprise a core and a coating, wherein the core comprises Fe3O4 or other magnetic material, and the coating has a thickness of about 1.5 nm to about 2 nm. The magnetic nanoparticles are useful for separating nucleic acids from other components and normalizing nucleic acid concentrations to produce nucleic acids for analysis.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to silica-coated magnetic nanoparticles (NPs), a composition comprising such magnetic nanoparticles, and a method for separating an analyte from a biological sample using such magnetic nanoparticles and the composition.

[0002] Cross-reference regarding related applications

[0003] This international application claims priority to international application number PCT / US2021 / 052974, filed on September 30, 2021, with the United States Patent and Trademark Office as the accepting office, the entire contents of which are incorporated herein by reference. Background Technology

[0004] Magnetic particles with various surface modifications are used to separate molecules from biological samples for further analysis and processing. The molecules to be analyzed are separated from other components of the sample by inducing the desired molecules to bind to the magnetic particles, applying an external magnetic field to capture the molecule-bound particles from the rest of the sample, washing the particles to remove contaminants, and finally recovering the desired molecules using water or a low ionic strength buffer.

[0005] Magnetic particles used for the separation of biomolecules generally contain magnetic iron oxide in their cores. These magnetic iron oxide particles typically exist as magnetite (Fe3O4), maghemite (γ-Fe2O3), or hematite (Fe2O3). For example, magnetic particles can be coated with silica, assuming a broad particle size distribution ranging from tens to hundreds of nanometers to several microns. Many synthesis methods for producing silica-coated magnetic particles result in materials with poorly defined (uneven) silica surfaces and / or large aggregates that precipitate from suspensions, making processing difficult. Consequently, particle mixing is required before and during the protocol to ensure maximum biomolecule binding and recovery of high-purity materials.

[0006] More specifically, silica-coated magnetic particles can be used to isolate nucleic acids from biological samples. The first example of capturing nucleic acids from a sample using silica was demonstrated by Vogelstein [Vogelstein, B. and Gillespie, D., Proc. Nalt. Acad. Sci. USA, 76 (2) 615-619, 1979]. He discovered that nucleic acids bind strongly to silica glass in the presence of chaotropic salts. The bound nucleic acids can be washed away with an aqueous organic solvent to remove contaminants while the nucleic acids remain bound to the silica. Upon exposure to a low ionic strength buffer, the nucleic acids are continuously released from the silica. If a reproducible synthetic method is developed to produce very small or optimally small silica-coated "nanoparticles," nucleic acids can be captured on the silica surface, contaminants can be washed away, and then eluted in a low ionic strength buffer without the associated problems of aggregation and subsequent precipitation.

[0007] The aforementioned nanoparticles (NPs) can be used in various nucleic acid purification protocols. For example, diagnostic methods relying on RNA enrichment of the SARS-CoV-2 virus, the etiological agent of COVID-19 disease, can be developed. The generated RNA can be detected by quantitative reverse transcription polymerase chain reaction (QRT-PCR). Once highly purified NP-based nucleic acids are provided, various analytical tools can be used to detect various other viral and bacterial infectious agents, such as Flu-A, Flu-B, and Legionella (which causes Legionellosis).

[0008] In addition, next-generation sequencing (NGS) protocols can be streamlined to increase sample throughput by using NPs to adjust each NGS library to the same specific target concentration (referred to as "normalization"). Normalizing multi-variable concentration NGS libraries allows the libraries to be pooled before loading them onto the sequencing instrument. This process enables sequencing multiple NGS libraries in a single sequencing run, thereby maximizing data collection and minimizing sequencing instrument costs.

[0009] There are several existing approaches for normalizing variable-concentration NGS libraries. These include nucleic acid quantification by spectrophotometry, fluorescence, quantitative PCR, or electrophoresis, followed by the calculation of the desired concentration and subsequent dilution of all samples to the normalized concentration. Other approaches for nucleic acid normalization include kits sold by Corning Life Sciences and other companies. According to the Corning "AxyPrep Mag PCR Normalizer" protocol, a 10 μL bead mixture has a binding capacity of 200 ng of input library DNA. The protocol advises that "to minimize variability within each data point, the input DNA must be at least 3–4 times higher than the desired DNA amount. For example, if the desired elution DNA concentration is 2 ng / μL, the sample input must be at least 8 ng / μL." Achieving such a quantity of library DNA (e.g., 400 ng DNA or a 200 nM concentration from a 50 μL library recovery volume) in sequencing projects is very difficult. This is especially true when the DNA used for NGS library synthesis is of poor quality, such as DNA characteristically recovered from formalin-fixed paraffin-embedded (FFPE) samples.

[0010] Agilent Technologies, Inc. (Santa Clara, California) currently offers kits for generating next-generation sequencing libraries, such as the "SureSelectXT Target Enrichment System." The SureSelectXT method generates libraries with total denormalized DNA amounts ranging from 10 nM to about 50 nM. These DNA amounts are estimated to be too low to use the AxyPrep Mag PCR Normalizer kit.

[0011] While the use of nucleic acid-based diagnostics and sequencing is increasing in research and medical diagnostics, pre-analysis nucleic acid preparation is a significant cost component of nucleic acid analysis technologies such as real-time PCR, nucleic acid sequencing, and hybridization testing. Sample preparation delays test results and limits the ability to perform these analyses, restricting them to laboratories with only well-trained personnel. Current sample preparation processes are laborious, time-consuming, and demanding of laboratory capacity.

[0012] There is still a need for magnetic nanoparticles and compositions that simplify and reliably generate purified nucleic acids from various sample types for diagnostic and research applications. Prior art literature

[65535] - Dao Van Quy, et al., Synthesis of Silica-Coated Magnetic Nanoparticles and Application in the Detection of Pathogenic Viruses, J. Nanomaterials , Vol. 2013, Article ID 603940 (2013)- U.S. Patent Application Publication No. 2011 / 0130616 (Publication Date: 2011.01.02.)- Japanese Patent Publication No. 2012-178539 (Publication Date: 2012.09.13.)- U.S. Patent Application Publication No. 2011 / 0064675 (Publication Date: 2011.05.17.)- Chinese Patent Publication No. 105869821 (Publication Date: 2016.08.17.)

[0013] As one aspect of the present technology, a stable aqueous dispersion of magnetic particles is provided. Each individual magnetic nanoparticle comprises a magnetic core and a uniform conformal coating surrounding the core. The homogeneous conformal coating has a thickness of about 1.5 nm to about 2 nm. The average total diameter of the individual homogeneous conformal-coated magnetic nanoparticles is about 10 nm to about 20 nm. In some examples, small clusters of magnetic nanoparticles are formed in the dispersion in a form having an average cluster size of about 50 nm to about 190 nm. In some examples, the clusters have an average cluster size of about 10 to about 1000 nm, for example, about 300 nm, in the dispersion.

[0014] As another aspect of the present technology, a method for preparing silica-coated magnetic nanoparticles is provided. Fe3O4 nanoparticles are provided in an alcohol mixture, and a silicate solution is added while sonicating the mixture. The thickness of the silica coating on the magnetic nanoparticles can be controlled by changing the amount of silicate added.

[0015] Particles manufactured using co-precipitation In some examples, the present method minimizes / eliminates the formation of unwanted Fe2O3 by excluding oxygen during the Fe3O4 co-precipitation reaction. In some examples, the coating thickness is selected to (1) protect the Fe3O4 core from further oxidation to Fe2O3, (2) completely cover the magnetic core, and (3) modify the surface chemistry of the resulting core-shell particles to include a high density of silanol groups (Si-OH) that makes the final particles more sensitive to nucleic acid binding. It has been found that coating thickness and surface area are important parameters regarding the utility and efficiency of the present magnetic particles for purifying nucleic acids from biological samples.

[0016] In another aspect, a method is provided for forming a stable and optimally sized cluster by maintaining an aqueous dispersion of the nanoparticles described herein ("aged" NP) during a clustering period. For example, the nanoparticles are maintained at room temperature or 20°C to 30°C during a clustering period which may be at least 1 month, or alternatively at least 2, 3, 4, 5, 6, 7, or 8 months, so that individual magnetic nanoparticles can form a cluster having an average cluster size (e.g., diameter) of a selected value or range. For example, the average cluster size may be about 200 nm or more, alternatively about 220 nm or more, alternatively about 235 nm or more, alternatively about 250 nm or more, alternatively about 260 nm or more, or the average cluster size may be up to about 400 nm, alternatively up to about 370 nm, alternatively up to about 350 nm, alternatively up to about 320 nm, alternatively up to about 300 nm, alternatively up to about 290 nm. It is clearly taken into consideration that any value of the aforementioned minimum and maximum values ​​may be combined to form a selected range, e.g., from about 200 nm to about 400 nm, alternatively from about 250 nm to about 350 nm. Using aged NPs compared to "unaged" NPs achieves enhanced nucleic acid detection in human clinical samples. In some embodiments, the aged NPs form clusters having an average cluster size of about 250 nm, about 255 nm, about 260 nm, about 265 nm, about 270 nm, about 275 nm, about 280 nm, about 285 nm, about 290 nm, about 295 nm, about 300 nm, about 305 nm, about 310 nm, about 315 nm, or about 320 nm; any of these values ​​are considered to be combined to form a range. Each of the aforementioned approximations is also additionally considered and specified as an initiation of a specific value.

[0017] In another aspect, a method for preparing nucleic acids for analysis is provided. The method comprises the steps of combining a sample containing nucleic acids in a container with a binding medium and a magnetic nanoparticle composition as described herein; binding the nucleic acids to a coating of magnetic nanoparticles; separating the nanoparticles from a liquid in the container using a magnetic field; removing the liquid from the container and retaining the nucleic acid-bound magnetic nanoparticles in the container; contacting the nucleic acid-bound magnetic nanoparticles with a washing solution to remove contaminants while the magnetic nanoparticles remain attracted to the magnet, or dispersing and then reattaching by a magnetic field, then removing the washing solution, and finally adding an elution medium to collect the nucleic acids released from the magnetic nanoparticles. The nucleic acids are removed from the container to provide a nucleic acid preparation.

[0018] As another aspect of the present invention, a method for obtaining RNA from a biological sample and preparing RNA for analysis is provided. The method comprises the step of placing a biological sample containing RNA into a container, wherein the biological sample is a cell or a virus. The biological sample is brought into contact with guanidine thiocyanate (GTC) and prodanase K to form a sample mixture, which is incubated at an elevated temperature during the sample preparation period. A composition of pure alcohol and magnetic nanoparticles (the embodiments thereof are described herein) is added to the sample mixture in the container. The method further comprises mixing the sample mixture with the magnetic nanoparticles and, after incubation for a second incubation period, applying a magnetic force to separate the magnetic nanoparticles from the supernatant in the container. After removing the supernatant from the container without stirring the separated magnetic nanoparticles, the container is washed one or more times with an alcohol solution. The separated magnetic nanoparticles are dried, and an elution medium is added to the container and mixed with the magnetic nanoparticles. After the elution period during which RNA is eluted from magnetic nanoparticles to form an eluate, the eluate is removed from the container.

[0019] These and other features and advantages of the method and composition will become apparent from the following detailed description together with the appended claims. Brief explanation of the drawing

[0020] Figures 1a and 1b illustrate examples of the preparation of silica-coated magnetic nanoparticles according to the present technology. Figures 2a and 2b are electron microscope images showing typical cluster sizes formed by individual silica-coated Fe3O4 nanoparticles and unaged particles in an aqueous dispersion. Figure 2c shows laser diffraction data of silica-coated magnetic nanoparticles according to the present technology. Figures 2d to 2i are TEM images of silica-coated magnetic nanoparticles prepared in Example 1. Figure 3 shows the full spectrum of silica-coated magnetic nanoparticles by FT-IR spectroscopy. The Fe-O stretching vibration at approximately 580 cm⁻¹ and the Si-O-Si stretching vibration at approximately 1100 cm⁻¹ are clearly visible. Figure 4 is a series of IR spectra highlighting the increase in the ratio of the Si-O peak to the Fe-O peak as the volume of TEOS used in the silica coating process increases (from 0.5 ml to 2.5 ml). A high ratio of the Si-O peak to the Fe-O peak is a signal that a thicker silica shell is formed on the Fe3O4 nanoparticle core. Figure 5 is a graph showing that the thickness of the silica coating increases linearly as the TEOS content increases. Figure 6 is a scanning electron microscope (SEM) image at 250,000x magnification of silica-coated magnetic nanoparticles according to the present technology. The particles were prepared by sonication with 1.5 ml of TEOS. Figure 7 is a transmission electron microscope (TEM) image of silica-coated magnetic nanoparticles according to the present technology. The typical range of the Fe3O4 core is 7 to 10 nm. The average silica coating thickness of the particles using 1.5 ml of TEOS was approximately 1.6 nm. The visible, prominent Fe3O4 crystal lattice seen inside the core indicates a lack of oxidation during synthesis. Figures 8a to 8f show the results of diagnostic quantitative reverse transcription polymerase chain reaction (QRT-PCR). Using manual (Figures 8a to 8c) and automated (Figures 8d to 8f) protocols and multiple lots of magnetic silica nanoparticles, viral RNA was recovered from samples and analyzed by diagnostic QRT-PCR. Figure 9 shows the results of "normalization" related to NGS. The presented data is an electrophoresis and next-generation sequencing data metric certification that the normalization defined below has been achieved. Figure 10 shows a photograph of the magnetic separation of silica-coated magnetic nanoparticles from a stable suspension using a small magnet. Figures 11a to 11k show the results of analysis with various parameters from the normalization of the NGS library. Figures 12a, 12b, 13a, and 13b show that the size of nanoparticle clusters increased due to aging. This lesson is best understood from the following detailed explanation when read in conjunction with the attached drawings. Featured parts are not necessarily drawn to scale. Specific details for implementing the invention

[0021] The silica-coated magnetic nanoparticles described herein (also abbreviated as “NP”) are surprisingly effective for isolating nucleic acids from samples. The silica coating provides a hydrophilic substrate, which significantly reduces non-specific binding in important applications such as nucleic acid purification.

[0022] In some embodiments, this technology is used for the enrichment of RNA obtained from cell or viral samples as part of a quantitative reverse transcription polymerase chain reaction (QRT-PCR) detection assay. For example, this technology may be used to enrich RNA from SARS-CoV-2 or other viral pathogens before detecting RNA by QRT-PCR. In some embodiments, this technology is used for the enrichment of human RNA and human and bacterial DNA. For example, this technology may be used to enrich and detect DNA from respiratory pathogens such as Legionella (the pathogen of Legionnaires' disease). In some embodiments, this technology is used for the normalization of DNA libraries prior to next-generation sequencing (NGS). In some embodiments, this technology is used to normalize DNA or RNA samples before analysis.

[0023] Referring to FIG. 1a, the present invention provides a magnetic nanoparticle (100) comprising a core (10) and a homogeneous conformal coating (20) on the core (10) that substantially encapsulates the core (10). In one example, the coating (20) completely encapsulates the core (10). The core (10) may be made of a metal, an alloy, or a metal oxide, and the coating may be made of silica. In one example, the core (10) may be Fe3O4, and the coating comprises silica. In one example, the silica coating is substantially non-porous. The ratio of the core diameter to the coating thickness and the characteristics of the coating surface may cause a plurality of magnetic nanoparticles (100) to aggregate in such a manner that an analyte in the sample solution can optimally bind to the surface of the coating of the magnetic nanoparticle (100). Magnetic nanoparticles (100) having an analyte bonded to a coated surface can be rapidly removed from a sample solution by applying a magnetic field to a sample solution having magnetic nanoparticles (100).

[0024] FIG. 1a illustrates an embodiment for the preparation of the magnetic nanoparticle (100). In one example, the magnetic nanoparticle (100) may have a size of about 9 nm to about 40 nm, for example, about 20 nm to about 30 nm. The core (10) may have a diameter of about 5 nm to about 20 nm, for example, about 7 nm to about 15 nm or less, for example, about 10 nm to about 15 nm or less, for example, about 8.8 nm or less, about 8 nm or less, or about 7.9 nm. The coating (20) substantially encapsulates the core (10). In some examples, the coating (20) may have a thickness of about 0.5 nm to about 7.5 nm, about 1 nm to about 2 nm, for example, about 1.5 nm to about 2 nm. FIG. 1b illustrates magnetic nanoparticles (100) having a coating thickness of about 2.5 nm and a particle size of about 15 nm.

[0025] The ratio of the core diameter to the thickness of the silica coating (20), combined with the properties of the silica coating (20), causes the magnetic nanoparticles (100) to aggregate to form clusters as illustrated in FIGS. 2a and 2b. In one example, the clusters are about 10 nm to about 1000 nm, e.g., about 20 nm to about 500 nm, about 100 nm to about 500 nm, about 200 nm to about 500 nm, about 250 nm to about 450 nm, about 275 nm to about 325 nm (e.g., It can be about 300 nm), about 30 nm to about 400 nm, or about 40 nm to about 300 nm. FIG. 2c shows laser diffraction data measured with Malvern Panalytical’s Mastersizer 3000, which illustrates the particle size distribution of a typical NP aqueous dispersion. Individual particles up to clusters with a diameter of about 1 micron are present in the dispersion, and the average cluster size is 128–174 nm in diameter. The nanoparticles in this example were “unaged”.

[0026] This NP exhibits high magnetic sensitivity in manual and automated workflows. This is particularly desirable in automated platforms where the timing and efficiency of magnetic particle capture are critical and rapid and quantitative particle collection is required during the capture, washing, and elution steps.

[0027] In some embodiments, the core of the nanoparticle consists mostly or entirely of an Fe3O4 crystal lattice. In some embodiments, the core of the nanoparticle is a single nanoscale crystal of magnetite (Fe3O4), or It consists mostly or entirely of single-domain magnetic nanoparticles of Fe3O4 exhibiting paramagnetism.

[0028] In some examples, NP is at least 105 m 2 / g, for example, at least about 110 m 2 / g to about 180 m 2 / g or at least about 110 m 2 / g to about 130 m 2 It has a Brunauer-Emmett-Teller (BET) surface area of ​​g / g. The BET surface area of ​​the NP can be measured by nitrogen adsorption technology. For example, nitrogen adsorption / desorption isotherms can be measured at liquid nitrogen temperature (-196°C) using a Micromeritics ASAP2020 volumetric adsorption analyzer for mesopority measurement.

[0029] The silica-coated magnetic nanoparticles described herein may be used directly or functionalized to meet the requirements of specific applications. Functional groups such as carboxylates, epoxides, and tosylates may be included in or added to the silica coating, and these functional groups may serve as a convenient method for covalent functionalization. As an additional example, the silica coating may also be modified by incorporating one or more types of organic groups into the silica matrix. The organic groups may covalently functionalize the surface and / or pores of the silica coating. As yet another example, a polymer may functionalize the silica surface by a simple coating or by covalent attachment.

[0030] The coating of silica magnetic nanoparticles described herein may include pores extending to the surface of the magnetic nanoparticles. The coating may be modified with functional groups inside and outside the pores. In some examples, the coating further includes reactive chemical residues configured to bind an analyte, such as nucleic acid.

[0031] The present invention provides a composition that may comprise a plurality of magnetic nanoparticles as described herein. The plurality of magnetic nanoparticles have an average particle size of about 15 nm or less, about 12 nm or less, or about 11 nm or less. The composition is a stable suspension of magnetic nanoparticles in a liquid medium such as water. In some examples, the magnetic nanoparticles are present in the stable suspension at a concentration of 3 to 30 g / L, or 10 to 20 g / L, or about 13 g / L.

[0032] In some examples, the nanoparticles are maintained in a suspended state at a temperature of 25°C for at least 6 months, or alternatively for at least 9 months. In some examples, the nanoparticles are maintained for an aggregation period before being used, shipped to a user, or released for general or specific use. The aggregation period is selected so that the nanoparticles form clusters of the desired size or characteristics. Exemplary aggregation periods include at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 6 months, at least about 8 months, or more; alternatively, exemplary aggregation periods include up to about 18 months, up to about 12 months, up to about 10 months, up to about 8 months, up to about 6 months, up to about 5 months or less; it is considered that a range may be formed by combining any of the aforementioned minimum and maximum values, provided that the minimum value is shorter than the maximum value. In some examples, a general use is to isolate analytes such as RNA from a sample. In some examples, a specific use is to normalize the amount of nucleic acid obtained from a sample.

[0033] The present technology also comprises a packaged stable suspension of magnetic nanoparticles. The magnetic particles or compositions described herein may be provided in a sealed package, wherein the internal volume of the sealed package is a suspension of nanoparticles in water.

[0034] The present technology provides a method for preparing silica-coated magnetic nanoparticles. The present method for preparing silica-coated magnetic nanoparticles involves adding a base (such as ammonia or NaOH) under an inert atmosphere at room temperature to Fe 3+ / Fe 2+ It includes the synthesis of magnetic iron oxide from an aqueous salt solution. Fe3O4 particles can be prepared using co-precipitation. The size, shape, and composition of the magnetic nanoparticles depend on the type of salt used (e.g., chloride, sulfate, nitrate), Fe 3+ / Fe 2+ It depends on the rain, reaction temperature, and pH value. Once the synthesis conditions are fixed, the final properties of the synthesized magnetite nanoparticles become fully reproducible. The advantages of this technique for Fe3O4 nanoparticle formation include rapid particle formation, the use of inexpensive solvents, magnetic separation for product isolation, controlled particle size and morphology, reproducible magnetic properties, and the ability to perform nanoparticle synthesis on a larger industrial scale. In some examples, the Fe+ concentration used for co-precipitation is less than 0.1 M, alternatively less than 0.05 M, alternatively less than 0.02 M, e.g., 0.01 M.

[0035] The above method is about 2 / 1 Fe 3+ / Fe 2+ Fe in molar ratio of deionized deoxygenated water 3+ and Fe 2+ It includes the step of preparing an aqueous solution of ions. In some examples, Fe in the aqueous solution 3+ The concentration is about 2 to about 50 mM, and Fe in the aqueous solution 2+ The concentration is about 1 to about 25 mM. Aqueous solutions can be prepared by dissolving FeCl3 and FeCl2 in deionized deoxygenated water, but other Iron salts may also be used. Water may be deoxygenated by any suitable technique, such as sparging with an inert gas, ultrasonic treatment, and / or stirring, for a sufficient deoxygenation period before combining with iron salts. The deoxygenation period is generally at least 2 hours, but longer or shorter periods may also be used.

[0036] Next, Fe 3+ and Fe 2+ The aqueous solution of the ions can be sonicated, and optionally, its temperature can be adjusted to about 35°C by heating the aqueous solution, for example, at room temperature. A base can be added to the heated aqueous solution under an inert atmosphere. In some examples, suitable bases include ammonia, sodium hydroxide, etc. The base is added in an amount sufficient to form an Fe3O4 core from the aqueous solution. For example, the base may be added in a molar excess of more than two times (e.g., four or eight times). After adding a sufficient amount of base As a result, a mixture containing Fe3O4 nanoparticles and alkaline water is formed. In some examples, a base may be added dropwise to the aqueous solution while optionally stirring and / or sonicating the aqueous solution.

[0037] The mixture is maintained under an inert atmosphere without stirring during the sedimentation period, during which Fe3O4 nanoparticles precipitate in alkaline water. In some examples, the sedimentation period is overnight or about 12 hours; in other examples, the settling period is at least 4, 6, 8, 12, or 18 hours, and / or up to 60, 48, 36, 24, or 20 hours; the aforementioned values ​​may be combined to form a range of sedimentation periods. After the sedimentation period, most of the alkaline water is removed from the mixture by aspiration. This provides a concentrated mixture of Fe3O4 nanoparticles in alkaline water.

[0038] Deoxygenated alcohol is added to the concentrated mixture to form an aqueous alcohol mixture. The aqueous alcohol mixture is stirred and sonicated to suspend Fe3O4 nanoparticles. In some examples, an additional base is added to the aqueous alcohol mixture prior to further processing.

[0039] A silicate solution is added to an aqueous alcohol mixture while sonicating and maintaining an inert atmosphere. The thickness of the silica coating can be controlled by the amount of reactants used. The silicate solution can be slowly added dropwise to the aqueous alcohol mixture over, for example, 30 to 90 minutes while stirring and sonicating the mixture. The silicate solution contains tetraethyl orthosilicate (TEOS) and alcohol. In some examples, the silicate solution is anhydrous.

[0040] This mixture is stirred under an inert atmosphere during the coating period, during which a silica coating is formed on the Fe3O4 nanoparticles. In some examples, the coating period is overnight or about 12 hours; in other embodiments, the coating period is 4, 6, 8, 12 or 18 hours or more, and / or 60 hours, 48 ​​hours, 36 hours, 24 hours or 20 hours or less; a combination of the aforementioned values ​​may form a range of coating periods.

[0041] Silica-coated Fe3O4 nanoparticles are separated from an alcohol aqueous mixture by any suitable separation technique. In some examples, Fe3O4 nanoparticles are separated from the aqueous alcohol mixture by magnetic capture. The silica-coated Fe3O4 nanoparticles may be washed with methanol or other alcohols or solvents. The separated silica-coated Fe3O4 nanoparticles may be dried, for example, by vacuum drying. By drying, a powder of silica-coated Fe3O4 nanoparticles is formed. In some examples, the powder containing silica-coated Fe3O4 nanoparticles is formed without milling or mechanically separating the nanoparticles.

[0042] The generated dried nanoparticles can be dispersed in deoxygenated water to form a composition. In some examples, the composition is a stable suspension. The generated particle suspension can be aged for up to 6 months to increase the average cluster size of the nanoparticles from an average of 125 nm to 260 nm.

[0043] The present invention also includes a method for preparing an analytical nucleic acid by separating a nucleic acid from a sample. In some examples, the method comprises the step of combining a sample containing a nucleic acid with a binding medium and a magnetic nanoparticle composition as described above in a container. The nucleic acid binds to a coating of the magnetic nanoparticles. After a binding period, the nucleic acid-bound magnetic nanoparticles are separated from the binding medium in the container. The nucleic acid-bound magnetic nanoparticles are brought into contact with a washing solution to remove unwanted contaminants, and then brought into contact with an elution medium to separate the bound nucleic acid from the magnetic nanoparticles. The magnetic nanoparticles are attracted by a magnet, and the resulting purified solution containing the desired nucleic acid is removed from the container to provide a nucleic acid preparation.

[0044] The magnetic nanoparticles and compositions described herein have various uses, such as separating analytes, such as small molecules, proteins, and / or nucleic acids, from biological samples. The magnetic nanoparticles and compositions may be used as carriers for chemical or biological species, including, for example, precious metal particles, small organic or inorganic molecules, DNA, peptides or polypeptides (e.g., antibodies and other proteins), and whole cells. Applications for such carriers may include magnetic resonance imaging (MRI), optical imaging, targeted drug delivery, and cell delivery.

[0045] The present invention provides a method for preparing an analytical nucleic acid. The method comprises the step of combining a sample containing the nucleic acid with a binding medium and a magnetic nanoparticle composition as described herein in a container. The nucleic acid binds to a coating of the magnetic nanoparticles. After the binding period, the magnetic nanoparticles bound to the nucleic acid are separated from the binding medium in the container. In some examples, the nucleic acid-bound magnetic nanoparticles are washed with a washing medium comprising an aqueous alcohol or various water-miscible organic solvents, such as acetonitrile, acetone, and sulfolane. Then, most of the liquid (binding medium and / or washing medium) is removed from the container while taking care to retain the nucleic acid-bound magnetic nanoparticles within the container. The nucleic acid-bound magnetic nanoparticles are brought into contact with an elution medium to separate the bound nucleic acid from the magnetic nanoparticles. The nucleic acid is removed from the container to provide a nucleic acid preparation.

[0046] The coating of magnetic nanoparticles may include binding moieties configured to selectively bind to nucleic acids or other analytes.

[0047] Isolating nucleic acids from a sample exemplifies the isolation of other analytes, for example, small molecules such as drugs, proteins or polypeptides, lipids, or other analytes.

[0048] This method can be used to normalize the amount of nucleic acid obtained from a sample. In this method, the sample contains an input amount of nucleic acid, and the magnetic nanoparticle composition has the ability to bind to an output amount of nucleic acid. The output amount is less than the input amount.

[0049] The magnetic nanoparticle composition may have a normalization factor of 0.8 to 1.2, where the normalization factor is the value obtained by dividing the concentration of nucleic acid recovered from the magnetic silica nanoparticles after exposure to a high concentration of nucleic acid by the concentration of nucleic acid recovered from the magnetic silica nanoparticles after exposure to a low concentration of nucleic acid. Ideally, for a composition prepared for NGS, the normalization factor will be about 1.0.

[0050] Nucleic acid preparations include nucleic acids having lengths within a predetermined length range. In some examples, the minimum nucleotide length is 50 nucleotides (nt), 70 nt, 75 nt, 80 nt, 100 nt, 150 nt, 200 nt, 500 nt, 2,000 nt or 5,000 nt or 10,000 nt, or 50,000 nt, or 100,000 nt; The maximum nucleotide length may be 2 million nt, 1 million nt, 500,000 nt, 200,000 nt, 75,000 nt, 25,000 nt, 12,500 nt, 6,000 nt, 3,000 nt, 1,500 nt, or 750 nt, or 400 nt, or 250 nt; as long as the minimum value is smaller than the maximum value, any value among the aforementioned minimum and maximum values ​​can be combined to form a desired nucleotide length range.

[0051] This method can be used as an input sample containing a small amount of nucleic acid, for example, less than 1,000 ng, less than 500 ng, less than 200 ng, less than 100 g, or less than 50 ng.

[0052] The present invention provides a method for obtaining RNA from a biological sample and preparing RNA for analysis. In this method, a biological sample containing RNA is placed in a container. The biological sample may be a cell or a virus.

[0053] This method comprises contacting a biological sample with guanidine thiocyanate (GTC) and proteinase K to form a sample mixture, and incubating it at a high temperature (e.g., about 60°C) for a sample preparation period (e.g., 10 minutes or less, or about 5 minutes). GTC and proteinase K may be added separately or pre-mixed and added together. After the sample preparation period, pure alcohol is added to the sample mixture in the container, and one of the magnetic nanoparticle compositions described herein is also added to the sample mixture in the container. The sample mixture and the magnetic nanoparticles are mixed and incubated for a second incubation period (e.g., 10 minutes or less, or about 5 minutes).

[0054] After the second incubation period, magnetic force is applied to separate the magnetic nanoparticles from the supernatant in the container. The supernatant is removed from the container without disturbing the separated magnetic nanoparticles, and then washed one or more times with an alcohol solution. Suitable alcohol solutions may contain at least 80% v / v of lower alcohols, such as methanol, ethanol, n-propanol, isopropanol, or mixtures thereof. A wide variety of non-alcoholic organic solvents that are miscible with water are also useful for the washing purposes and are known to those skilled in the art. Some of these include, but are not limited to, acetonitrile, acetone, and sulfolan. The separated magnetic nanoparticles are dried, and an elution medium is added to the container. The magnetic nanoparticles are mixed with the elution medium during an elution period (e.g., less than 10 minutes), after which RNA is eluted from the magnetic nanoparticles to form an eluent. After removing the RNA-containing eluent from the container, the RNA can be applied to analyses such as quantitative reverse transcription polymerase chain reaction (QRT-PCR) for diagnostic and research purposes, or modified and used as a substrate for nucleotide sequencing, such as Sanger and NGS sequencing. Alternatively, the removed eluent can be placed in a second container, sealed, and stored at a reduced temperature for transport or subsequent analysis.

[0055] In some examples, one, several, or all steps of the aforementioned method are performed by an automated device.

[0056] Glossary of Terms

[0057] It should be understood that the terms used in this specification are merely for describing specific embodiments and are not intended to be limiting. Defined terms are added to the technical and scientific meanings of the defined terms as generally understood and accepted in the technical field of this teaching.

[0058] In this document, the terms “nucleic acid” and “polynucleotide” are used interchangeably to describe polymers of any length, e.g., greater than about 10 bases, greater than about 100 bases, greater than about 500 bases, greater than 1,000 bases, greater than 10,000 bases, or greater than or equal to length, composed of nucleotides (e.g., deoxyribonucleotides or ribonucleotides) or synthetic-generated compounds capable of hybridizing with naturally occurring nucleic acids in a sequence-specific manner similar to that of two naturally occurring nucleic acids (e.g., capable of participating in Watson-Crick base pair interactions). Naturally occurring nucleotides include guanine, cytosine, adenine, thymine, and uracil (G, C, A, T, and U, respectively).

[0059] The terms "complementary," "complementary," or "complementary nucleic acid sequence" refer to a nucleic acid strand associated with the base sequence of another nucleic acid strand according to the Watson-Crick base pairing rules. Generally, two sequences are complementary when one sequence can hybridize with another sequence in an antiparallel sense, where the 3'-end of each sequence hybridizes to the 5'-end of the other sequence and each of the A, T / U, G, and C of one sequence aligns with the T / U, A, C, and G of the other sequence, respectively.

[0060] The term "duplex" refers to the process in which at least two sequences that are completely or partially complementary undergo Watson-Crick type base pairing to form a stable complex between all or most of their nucleotides. The terms "annealing" and "hybridization" are used interchangeably to refer to the formation of a stable duplex.

[0061] With respect to nucleotide sequences, the terms "hybridization" and "hybridizing" are used interchangeably herein. The ability of two nucleotide sequences to hybridize with each other is based on the degree of complementarity between the two nucleotide sequences, which is based on the fraction of matched complementary nucleotide pairs. The more nucleotides in a given sequence that are complementary to another sequence, the stricter the conditions for hybridization may become, and the hybridization of the two sequences will be more specific. Stringency can be increased by methods such as increasing the temperature, increasing the ratio of co-solvent, and lowering the salt concentration.

[0062] When used in the specification and the appended claims, the terms “substantial” or “substantially” mean, in addition to their general meanings, that they are within the limits or extent permissible to a person skilled in the art. For example, “substantially cancelled” means that a person skilled in the art would consider the deletion to be permissible.

[0063] When used in the specification and the appended claims, the terms “approximately” and “about” mean, in addition to their general meanings, that they are within the limits or amounts acceptable to a person skilled in the art. The term “about” generally means plus or minus 15% of the indicated figure. For example, “about 10” may indicate a range of 8.5 to 11.5. For example, “approximately identical” means that a person skilled in the art would consider the items being compared to be identical.

[0064] In this disclosure, numerical ranges include the numerical value defining the range. It should be recognized that chemical structures and formulas may be elongated or expanded for illustrative purposes.

[0065] Unless otherwise defined, all technical and scientific terms used in this document have the same meaning as generally understood by persons working in the field related to this disclosure.

[0066] Before describing various embodiments, it should be understood that the teachings of this disclosure are not limited to the specific embodiments described and are therefore naturally subject to variation. Furthermore, it should be understood that the terms used herein are for the purpose of describing specific embodiments only, and are not intended to be limiting, as the scope of these teachings will be limited only by the appended claims.

[0067] As disclosed in this specification, a plurality of value ranges are provided. Unless the context clearly indicates otherwise, it should be understood that each intermediate value between the upper and lower limits of such ranges is specifically disclosed in units of one-tenth of the lower limit unit.

[0068] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as generally understood by those skilled in the art to which this disclosure pertains. Any method and material similar or equivalent to that described herein may also be used in the practice or testing of this teaching, but some exemplary methods and materials are described hereafter.

[0069] All patents and publications mentioned in this specification are expressly incorporated by reference.

[0070] Singular terms used in the specification and appended claims include both singular and plural subjects unless otherwise specified in the context. Thus, for example, "moiety" includes one moiety and multiple moietys.

[0071] Examples

[0072] Example 1

[0073] In this example, silica-coated magnetic nanoparticles (NPs) were prepared using the methods described above and below. An exemplary procedure for synthesizing Fe3O4 nanoparticles on a 1 g scale was performed as follows: 400 ml of DI water was extensively deoxygenated for 2 hours using hard N2 purging, mechanical stirring, and sonication. Once deoxygenated, 2.508 g of FeCl3 (9.24 mM) and 0.919 g of FeCl2 (4.62 mM) were added under nitrogen, followed by further purging and sonication. During the sonication process, the water temperature was increased to 35°C. Subsequently, 10 ml of a 28% ammonia solution was rapidly added to the rapidly stirred and sonicated solution (0.18 M, which is approximately 4 molar excess required to completely convert iron into magnetite). The solution immediately turned black with nanoparticle precipitates. The sonication treatment was stopped, and the mixture was stirred under nitrogen for an additional 4 hours. Afterward, the particles were left under nitrogen without stirring until the next day. The nanoparticles settled at the bottom of the flask, producing a transparent upper aqueous layer and a black bottom layer composed of magnetic Fe3O4 nanoparticles.

[0074] The next day, the precipitated Fe3O4 nanoparticles were isolated by removing the clear ammonia / water top layer via suction. The remaining solvent (100 ml) was left in place. Subsequently, 300 ml of deoxygenated ethanol was added to the black slurry. The particles were stirred for 1 hour and sonicated to resuspend the nanoparticles. During sonication, 1.5 ml of TEOS was mixed with 80 ml of anhydrous ethanol, added to an addition funnel under nitrogen purging, and mounted in a flask. The flask was purged and then sealed under a flow of N2. Subsequently, 5 ml of an additional ammonia solution (28%) was added to the black nanoparticle suspension. The mixture was sonicated again and mechanically stirred for 10 minutes under a flow of nitrogen. Then, the TEOS solution was added dropwise over approximately 60 minutes, and the nanoparticles were stirred and sonicated. After adding the TEOS solution, slow stirring was continued overnight under N2.

[0075] The next day, the nanoparticles were isolated from the bottom of the flask using a magnet. A clear ethanol / water mixture was decanted from the nanoparticles held in place by the magnet. The silica-coated Fe3O4 nanoparticles were washed twice with fresh methanol and then magnetically separated. The nanoparticles were then dried into a powder under a stream of nitrogen and dispersed in 100 ml of deoxygenated water. The nanoparticles were extensively sparged with nitrogen, sonicated, and then sealed under an inert atmosphere to produce a 1.3 wt% nanoparticle solution in water.

[0076] To perform various analyses, samples of silica-coated Fe3O4 nanoparticles were isolated into dry particles. The particles were imaged using a scanning electron microscope (SEM) to approximate the degree of aggregation and overall size of individual particles. Figures 2a and 2b are scanning electron microscope (SEM) images of silica-coated magnetic nanoparticles according to the present technology. Figure 2c shows laser diffraction data of silica-coated magnetic nanoparticles according to the present technology.

[0077] Using current techniques that include ultrasonic treatment during synthesis helps disperse the nanoparticle cores, resulting in a uniform silica coating and preventing premature particle aggregation. SEM estimates indicate that the final silica-coated Fe3O4 nanoparticles have a diameter of 10 to 15 nm. This suggests that the core / coating structure consists of inner Fe3O4 nanoparticles with a diameter of approximately 7–10 nm, containing an outer uniform shell of silica with a thickness of approximately 1.5 nm. These sizes were confirmed using high-resolution TEM.

[0078] Examples 1-1, 1-2, and 1-3 were prepared using the aforementioned technique with different amounts of TEOS solution. The silica-coated Fe3O4 nanoparticles were analyzed by IR and TEM and were confirmed to have very desirable size characteristics and a SiO:FeO ratio. FIGS. 2d and 2e are TEM images for Example 1-1, FIGS. 2f and 2g are TEM images for Example 1-2, FIGS. 2f and 2g are TEM images for Example 1-2, and FIGS. 2H and 2I are TEM images for Example 1-3. The following table provides the average shell thickness and average core particle size for each example.

[0079]

[0080] In the table above, the amount of TEOS used in the reaction is presented in terms of volume and equivalents. The ratio of SiO to FeO in the generated silica-coated nanoparticles was determined by IR analysis. Shell thickness and core particle size were determined based on TEM analysis.

[0081] Analysis of dried silica-coated Fe3O4 nanoparticles using Brunauer-Emmett-Teller (BET) theory revealed that the material surface area is 105 m² 2 Exceeding / g (e.g., 113-127 m 2It was found to be ( / g), which is in good agreement with the estimated particle diameter. Analysis of the nanoparticles was also performed using FT-IR spectroscopy before and after functionalization with a silica shell. FT-IR analysis of uncoated Fe3O4 nanoparticles revealed 580 cm⁻¹ associated with the metal-oxygen-Fe-O stretching vibration of the crystal lattice of the Fe3O4 magnetic phase. -1 and 630 cm -1 It shows two overlapping bands at 3400 cm⁻¹. After coating the nanoparticles with silica, these bands arise from the silica OH stretching and Si-O stretching of the SiO₂ shell. -1 , 1094 cm -1 and 467 cm -1 It is combined by an additional mode (see Fig. 3). The emergence of a new mode confirmed that the nanoparticles were encapsulated in a thin silica shell.

[0082] Two other batches of silica-coated nanoparticles were prepared in the same manner as in Example 1-1, and the coating thickness was evaluated. As shown in the table below, this procedure produced silica-coated nanoparticles with a very uniform coating thickness with almost no batch-to-batch variability.

[0083]

[0084] Example 2

[0085] In this embodiment, silica-coated nanoparticles were prepared according to the procedure described in Example 1, except that different amounts of silicate were used in the procedure of Example 1. The table below summarizes five different embodiments of magnetic nanoparticles prepared in this embodiment.

[0086]

[0087]

[0088] Silica-coated magnetic nanoparticles were analyzed by FT-IR, and Figure 4 shows the spectrum. Particles of various embodiments have different silica coating thicknesses. IR analysis showed that the silica coating thickness increased linearly as the amount of TEOS increased.

[0089] Figure 5 is a graph showing that the thickness of the silica coating increases linearly as the TEOS content increases.

[0090] Figure 6 is a scanning electron microscope (SEM) image at 250,000x magnification of silica-coated magnetic nanoparticles according to the present technology. The particles were prepared by sonication with 1.5 ml of TEOS.

[0091] Figure 7 is a transmission electron microscope (TEM) image of silica-coated magnetic nanoparticles according to the present technology. Individual silica-coated magnetic nanoparticles can be seen. Particle aggregation can also be observed. The typical Fe3O4 core is in the range of 7 to 10 nm. The average silica coating thickness of the particles using 1.5 ml of TEOS was approximately 1.6 nm. The Fe3O4 crystal lattice is visible inside the core, indicating that the nanoparticles were not oxidized during synthesis or transport.

[0092] Example 3

[0093] In this example, Examples 3-1 to 3-14 were prepared by manufacturing several lots of silica-coated magnetic nanoparticles according to the procedure described in Example 1. The surface area of ​​some of these examples was determined by the Brunauer-Emmett-Teller (BET) surface area, which is approximately 113 m² 2 / g to about 127 m 2 It was found to have a surface area of ​​ / g.

[0094]

[0095] Example 4

[0096] In this example, RNA was recovered from a sample using the magnetic nanoparticles of the present invention in both manual and automatic protocols. In this method, a 75 μL aliquot of a biological sample containing RNA was pipetted into a 0.2 ml strip tube. 75 μL of guanidine thiocyanate (GTC) containing lysis buffer and 2 μL of proteinase K (20 mg / ml) were added to each tube. The tubes were capped, mixed by vortexing, and spun. The tubes were incubated at 60°C for 5 minutes. After incubation, 75 μL of 100% EtOH was added to each tube along with 2 μL of magnetic nanoparticles having a particle size of 10.38 nm based on a core particle size of 8.82 nm and a coating thickness of 1.56 nm. The tube was capped, mixed, briefly spun, and incubated at room temperature for 5 minutes. During this second incubation period, RNA from the sample was bound to silica-coated magnetic nanoparticles.

[0097] After the second incubation period, the tube was placed on a magnet for 5 minutes. Then, all the supernatant was removed from the tube without disturbing the nanoparticle pellet. 200 μL of washing medium (80% EtOH) was added to the pellet in the tube. The washing medium was removed without disturbing the nanoparticle pellet, and the washing and removal steps were repeated. The nanoparticle pellet was incubated at room temperature for 3 minutes to dry the nanoparticles.

[0098] Then, 75 μL of elution medium preheated to 65°C was added to the tube, and the nanoparticles were mixed by pipetting up and down several times to avoid the formation of air bubbles. After letting the tube stand for 2 minutes, the nanoparticles were captured with a magnet, and the RNA-containing eluent was recovered and transferred to a new tube. The new tube was capped and placed on ice.

[0099] Example 5

[0100] In this example, RNA was recovered from a sample using the magnetic nanoparticles of the present invention in a manual protocol. FIG. 8a compares six lots of nanoparticles (NP) for viral RNA extraction using a manual workflow.

[0101] SARS-CoV-2 armored synthetic RNA at 10 SARS-CoV-2 N1 and N2 targets per microliter in nasal swabs (NS) collected by VTM 5 , 10 4 , 10 3 , 10 2 Samples designed by spiking in at final concentrations of , 10, 1, and 0.5 copies were prepared. RNA extraction was performed using 75 µl of each dilution in duplicate according to the NAP manual protocol. Specifically, 75 µl of each sample was mixed with 75 µl of lysis buffer and 2 µl of prodanase K, incubated at room temperature for 5 minutes, and at 60°C for 5 minutes, after which 75 µl of 100% ethanol containing 2 µl of nanoparticle beads was added. The following six nanoparticle lots were used in this experiment: Examples 3-3, 3-5, 3-6, 3-7, 3-8, and 3-9. The sample was mixed and incubated at room temperature for 5 minutes to allow the nucleic acids to bind to the magnetic beads, then the tube was transferred to a magnetic stand and the beads were collected from the bottom of the tube (RNA remains bound to the magnetic beads at this stage). After aspirating the supernatant, the beads were washed twice with 80% ethanol, dried at room temperature for 3 minutes, and the RNA was eluted with 30 µl of low TE buffer (10 mM Tris, 0.1 mM EDTA, pH 8.0).

[0102] 5 µl of each extracted RNA sample was used for a multiplex QRT-PCR reaction using primers and probes specific to SARS-CoV-2 N1 and N2 targets and the human RNase P gene. The analysis was performed on an Agilent AriaMx Real-Time PCR system. Amplification curves for N1, N2, and RP targets are provided in Figures 8a, 8b, and 8c, and the corresponding Cqs are provided in Tables A, B, and C. No significant differences were observed between the six nanoparticle lots, and 10 5 -0.5 QRT-PCR detection of SARS-CoV2 N1 and N2 RNA targets in copy / ul and human RP were demonstrated.

[0103] [Table A]

[0104]

[0105] [Table B]

[0106]

[0107] [Table C]

[0108]

[0109] Example 6

[0110] In the following examples, RNA was recovered from samples using the magnetic nanoparticles of the present invention in an automated protocol. Figures 8d, 8e, and 8f compare six lots of nanoparticles for viral RNA extraction using an automated workflow.

[0111] SARS-CoV-2 protective synthetic RNA in 10 SARS-CoV-2 N1 and N2 targets per microliter in collected nasal swabs (NS) as a viral delivery medium (VTM) 5 , 10 4 , 10 3 , 10 2Samples designed by spiking to final concentrations of , 10, 1, and 0.5 copies were prepared. RNA extraction was performed using 75 µl of each dilution. Subsequently, 75 µl of each sample was mixed with 75 µl of lysis buffer and 2 µl of prodanase K, incubated at room temperature for 5 minutes, and then transferred to a Bravo instrument for automated processing. The following nanoparticle lots were used in this experiment: Example 3-2, Example 3-3 (two different vials designated as 3-3a and 3-3b), Example 3-4, Example 3-5, and Example 1-1B. RNA was eluted with 30 µl of low TE buffer (10 mM Tris, 0.1 mM EDTA, pH 8.0).

[0112] 5 µl of each extracted RNA sample was used for a multiplex QRT-PCR reaction using primers and probes specific to SARS-CoV-2 N1 and N2 targets and the human RNase P gene. The analysis was performed on an Agilent AriaMx Real-Time PCR system. Amplification curves for N1, N2, and RP targets are provided in Figures 8d, 8e, and 8f, and the corresponding Cqs are provided in Tables D, E, and F. No significant differences were observed between the six nanoparticle lots, and 10 5 -0.5 QRT-PCR detection of SARS-CoV2 N1 and N2 RNA targets in copy / ul and human RP were demonstrated.

[0113] [Table D]

[0114]

[0115] [Table E]

[0116]

[0117] [Table F]

[0118]

[0119] Example 7

[0120] In this experiment, the NP aging effect on the average cluster size was evaluated. Figures 12a and 12b illustrate the increase in cluster size as the nanoparticle composition of the present invention is aged up to 218 days. Table H shows the values ​​measured at the indicated time points.

[0121] [Table H]

[0122]

[0123] Figures 13a and 13b illustrate another experiment demonstrating an increase in cluster size as another nanoparticle composition of the present invention is aged up to 109 days. Table I shows the values ​​measured at the indicated time points.

[0124] [Table I]

[0125]

[0126] These experiments show that the nanoparticle mode size increases over the cluster period and is leveled off at approximately 300 nm, more specifically at about 260 nm. Nanoparticle compositions containing clusters of this size were used for exemplary RNA isolation / QRT-PCR analysis and NGS normalization.

[0127] Example 8

[0128] In this example, the effect of NP aging on nucleic acid extraction efficiency was evaluated by comparing QRT-PCR analysis of RNA isolated using 2-week-old and 14-week-old NPs. Nucleic acids were extracted from 14 nasopharyngeal (NP) clinical samples, of which 8 were known positive for human metapneumovirus (hMPV) and 6 were known positive for human parainfluenza 3 virus (hPIV3). The amount of extracted viral RNA was evaluated by QRT-PCR in the AriaMx Real-Time PCR System using Brilliant III QRT-PCR reagent, ABI TaqMan microbiological assay (primers and probes for detecting hMPV or hPIV3), and 2 μl of each RNA sample in a 20 μl PCR reaction. The results were analyzed using AriaMx v1.5 software (the ΔCq value for each sample was calculated as [ΔCq = Cq 2 weeks - Cq 14 weeks]), and the data are described in the table below.

[0129] As shown in Table G, 10 out of 14 samples (71%) extracted using 14 weeks of NP showed >0.5 Cq improvement (ΔCq 1 = 3-fold difference in RNA yield).

[0130] [Table G]

[0131]

[0132] This experiment demonstrated that the 14-week NP composition ("aged" NP composition) provided a significant improvement in viral RNA yield from clinical samples when measured by QRT-PCR.

[0133] Example 9

[0134] In the following examples, DNA samples destined for NGS, referred to as a "library," were "normalized" with different concentrations, which means that all DNA concentrations generated after normalization have nearly the same concentration regardless of the DNA concentration to which the magnetic silica nanoparticles were exposed.

[0135] The following steps were all performed at 4℃.

[0136] 10 μL (0.1 μg / mL; 1 μg) of magnetic nanoparticles and 60 μL of DNA binding medium were added to tubes A1-H1 (nanoparticle lot CS-019A) and A2-H2 (nanoparticle CS-019B) and mixed by pipetting.

[0137] 20 μL of 10 nM DNA library is added to tubes A1-D1 and A2-D2, 20 μL of 100 nM DNA library is added to tubes E1-H1 and E2-H2, and the particles are captured immediately after mixing by pipetting.

[0138] The captured particles were washed once with 150 μL of 80% EtOH, the supernatant was removed, the particles were dried, 10 μL of 10 mM Tris-0.1 mM EDTA (pH 8.0) was added and mixed, the particles were immediately captured, and electrophoretic analysis (HSD1000 TapeStation) was performed on the supernatant.

[0139] Figure 9 shows the TapeStation analysis results. Despite the difference in nucleic acid concentrations of the DNA libraries used as inputs for the normalization method, the normalization factor was 1.1 for CS-019A and 1.0 for CS-019B. The average DNA concentrations from tubes A1 to D1 and E1 to H1 (CS-019A) were 9.4 nM and 10.4 nM, respectively. Dividing 10.4 by 9.4 gives an essentially normalization factor of 1.1. The average DNA concentrations from tube A2 to D2 and from E2 to H2 (CS-019B) were 9.8 nM and 9.7 nM, respectively. Dividing 9.8 by 9.7 gives an essentially normalization factor of 1.0.

[0140] Example 10

[0141] In this embodiment, DNA samples (or libraries) for NGS at different concentrations were normalized. This embodiment further demonstrates that normalizing variable-concentration nucleic acid libraries using NPs can improve NGS protocols, thereby increasing sample throughput and reducing sequencing instrument time and cost. NGS instrument platforms typically require nucleic acids of a specific concentration to be loaded into the sequencing instrument. If the concentration is too low or too high, the output and quality of the sequence data deteriorate. There are several existing approaches for normalizing variable-concentration nucleic acids for NGS. These include nucleic acid quantification by spectrophotometry, fluorescence, quantitative PCR, or electrophoresis, followed by the calculation of the desired concentration, and then the dilution of all samples to the normalized concentration. The following NGS data comparison demonstrates NP normalization quality that is equal to or higher than that of electrophoresis (Agilent TapeStation device).

[0142] The normalization procedure described in Example 8 was used with silica-coated magnetic nanoparticles (nanoparticle lot CS-019) prepared according to Example 1.

[0143] The results are illustrated in FIGS. 11a through 11j. In the figures, BN represents the NP-normalized library, and TS represents the TapeStation-normalized library. FIG. 11a shows the TapeStation analysis results.

[0144] Figure 11b shows the "bam count," which is the number of sequence reads mapped to each feature of interest, such as genes, exons, and transcripts. The bam count was lower but more uniform for the NP-normalized library compared to the TS-normalized library.

[0145] Figure 11c shows the complexity of the normalized library, reflecting the amount of bias generated by the given experimental design. In terms of library complexity, the ideal is a very complex library that faithfully reflects the intrinsic complexity of the source material. NP and TS normalization produced the same complexity, as indicated by nearly identical coefficients of variation. The NP-normalized library and the TS-normalized library were equally complex.

[0146] Figure 11d shows the uniformity of the normalized library, which is the percentage of targeted base locations where the read depth is greater than a defined number of times the average area target coverage depth. The NP-normalized library was more uniform than the TS-normalized library.

[0147] Figure 11e shows the coverage of the normalized library. The number of times a specific base within a target region appears in the sequence data is called coverage or depth of coverage. The number before 'x' is the coverage (the average number of times the genome is sequenced). For example, in the case of 30x whole genome sequencing (WGS), '30x' means that the entire genome is sequenced an average of 30 times. NP and TS normalization provided the same results for both 20X and 30X coverage.

[0148] Figure 11f shows the "Fold 80" base pair penalty, which is the number of additional sequencing folds required to ensure that 80% of the target bases achieve average coverage. As the on-target rate decreases or Fold 80 increases, capture inefficiency and wasted sequencing increase. NP normalization had an average "Fold 80" of 3, whereas TS normalization had an average "Fold 80" of 3.25, meaning that fewer sequencings are required for the NP-normalized library compared to the TS-normalized library. A lower Fold 80 number indicates better results.

[0149] Figure 11g shows the duplication of the normalized library. A multiple sequencing read is considered a duplicate read if it maps to exactly the same location, including the coordinates of the 3' and 5' ends. The duplication rate is the proportion of mapped reads marked as duplicate reads in a specific dataset; duplicate reads do not provide additional information and are removed from the sequencing data during bioinformatics analysis known as deduplication. NP normalization and TS normalization provided the same duplication value.

[0150] Figure 11h shows AT / GC dropout. AT / GC dropout metrics indicate the degree of inadequate coverage in specific regions based on AT or GC content. For the NP-normalized library and the TS-normalized library, the values ​​for these metrics were identical.

[0151] Figure 11i shows the average insertion size. The insertion size is the length of the DNA (or RNA) to be sequenced and is "inserted" between adapters. For the NP-normalized library, the average insertion size is 220 bp, and for the TS-normalized library, the average insertion size is 190 bp, which is 30 bp higher than for the NP-normalized library.

[0152] Figure 11j shows the on-target values ​​for the normalized library. The on-target base percentage is the number of bases mapped to the target region, and the on-target read percentage includes all sequencing reads that uniformly overlap the target region by a single base. The more bases or reads belonging to the target region, the higher the overall on-target ratio, which indicates strong probe specificity, high-quality probes, and efficient hybridization-based target enhancement. The difference between the NP-normalized library and the TS-normalized library was only 0.03%.

[0153] It is noted that, with regard to the present disclosure, the method, composition, and system may be implemented while maintaining the teachings of this disclosure. Furthermore, various components, materials, structures, and parameters are included merely for illustrative and illustrative purposes and are not intended to be limiting. With regard to the present disclosure, the teachings of this disclosure may be implemented in other applications, and components, materials, structures, and equipment for implementing such applications may be determined within the scope of the appended claims.

Claims

Claim 1 A composition comprising magnetic nanoparticles in a liquid medium, wherein each of the magnetic nanoparticles comprises a magnetic core and a coating on the core, the coating having a thickness of 1 nm to 2 nm, and the magnetic nanoparticles of the composition are 110 m 2 / g to 130 m 2 A composition having a Brunauer-Emmett-Teller (BET) surface area of ​​g / g, wherein the composition comprises clusters of individual magnetic nanoparticles, and the clusters have an average cluster size of 250 nm to 350 nm. Claim 2 A composition according to claim 1, wherein the coating has a thickness of 1.5 nm to 2.0 nm. Claim 3 In claim 1, the magnetic nanoparticle is 113 m 2 / g to 127 m 2 having a BET surface area of ​​ / g, Composition. Claim 4 A composition according to claim 1, wherein the individual magnetic nanoparticles have an average total diameter of 15 nm or less. Claim 5 A composition according to claim 1, wherein the individual magnetic nanoparticles have an average total diameter of 10 to 15 nm. Claim 6 A composition according to claim 1, wherein the average diameter of the magnetic nanoparticle core is 10 nm or less. Claim 7 A composition according to claim 1, wherein the core is a single-domain magnetic nanoparticle of Fe3O4 exhibiting paramagnetism. Claim 8 A composition according to claim 1, wherein the core is a single nanoscale crystal of magnetite. Claim 9 A composition according to claim 1, wherein the core does not contain Fe2O3. Claim 10 A composition according to claim 1, wherein the coating comprises silica. Claim 11 A composition according to claim 1, wherein the coating further comprises a binding moiety that binds an analyte. Claim 12 A composition in which the analyte in Clause 11 is nucleic acid. Claim 13 A composition according to claim 1, wherein the liquid medium is water. Claim 14 A composition according to claim 13, wherein the composition is a stable aqueous dispersion. Claim 15 In claim 13, the composition comprises a cluster of magnetic nanoparticles dispersed in water. Claim 16 A composition according to claim 15, wherein the cluster has an average cluster size of 300 nm. Claim 17 A composition according to claim 1, wherein the composition is a suspension of stable magnetic nanoparticles, and the magnetic nanoparticles are present at a concentration of 3 to 30 g / L. Claim 18 A composition according to claim 17, wherein the magnetic nanoparticles are maintained in a suspended state at a temperature of 25°C for at least 6 months. Claim 19 A composition according to claim 17, wherein the suspension of the stable magnetic nanoparticles is packaged in a sealed package, and the internal volume of the sealed package is oxygen-free. Claim 20 As a method for preparing silica-coated magnetic nanoparticles, 2 / 1 Fe 3+ / Fe 2+ Fe in deionized, de-oxygenated water by molar ratio 3+ and Fe 2+ aqueous solution of ions A method comprising the steps of: manufacturing; ultrasonically treating the aqueous solution; precipitating Fe3O4 from the aqueous solution to form a mixture containing Fe3O4 nanoparticles; adding a deoxygenated alcohol and a silicate to the mixture; forming a silica coating on the Fe3O4 nanoparticles; separating the silica-coated Fe3O4 nanoparticles from the mixture; and maintaining the silica-coated Fe3O4 nanoparticles during a clustering period to form a cluster of individual magnetic nanoparticles having an average cluster size of 250 nm to 350 nm. Claim 21 In item 20, Fe in the above aqueous solution 3+ The concentration is 2 to 50 mM, and Fe in the aqueous solution 2+ A method having a concentration of 1 to 25 mM. Claim 22 In paragraph 20, the above aqueous solution is prepared by dissolving FeCl3 and FeCl2 in deionized deoxygenated water, method. Claim 23 A method according to claim 20, further comprising the step of adding a base to the aqueous solution under an inert atmosphere. Claim 24 A method according to paragraph 23, wherein the base is ammonia and the base is added in a molar excess of at least two times. Claim 25 A method according to claim 23, further comprising the step of maintaining the mixture under an inert atmosphere without stirring during a settling period in which F3O4 nanoparticles are settled from the mixture; and the step of concentrating the mixture of Fe3O4 nanoparticles by removing most of the water from the mixture after the settling period. Claim 26 A method according to claim 25, further comprising the step of stirring during the coating period under an inert atmosphere. Claim 27 A method according to claim 26, wherein the immersion period is 8 to 24 hours, the coating period is 8 to 24 hours, or both the immersion period and the coating period are 8 to 24 hours. Claim 28 A method according to claim 20, further comprising the step of adding an additional base to the mixture and then adding an anhydrous silicate solution. Claim 29 A method according to claim 20, wherein silicate is added dropwise to the mixture while stirring and ultrasonically treating the mixture. Claim 30 A method according to claim 20, wherein the Fe3O4 nanoparticles are separated from the mixture by magnetic capture, and the method further comprises the step of washing the silica-coated Fe3O4 nanoparticles with methanol. Claim 31 A method according to claim 20, further comprising the step of vacuum drying separated silica-coated Fe3O4 nanoparticles to form a powder of silica-coated Fe3O4 nanoparticles. Claim 32 A method according to claim 31, further comprising the step of dispersing the powder in deoxygenated water, sparging with an inert gas, ultrasonically treating, and then sealing within a package under an inert atmosphere. Claim 33 A method according to claim 20, wherein the silica-coated Fe3O4 nanoparticles are maintained at a temperature of 20°C to 30°C during the clustering period. Claim 34 In paragraph 20, a method in which the clustering period is one month or more. Claim 35 delete Claim 36 delete Claim 37 delete Claim 38 delete Claim 39 delete Claim 40 delete Claim 41 delete Claim 42 delete Claim 43 delete Claim 44 delete Claim 45 delete Claim 46 delete Claim 47 delete Claim 48 delete Claim 49 delete Claim 50 delete Claim 51 delete Claim 52 delete Claim 53 delete Claim 54 delete

Citation Information

Patent Citations

  • Preparation method of magnetic liquid

    CN105869821A

  • Functional particle with rough-surface polymer coating applied thereto

    JP2012178539A

  • Elemental iron nanoparticles

    US20110064675A1

  • Magnetically Responsive Nanoparticle Therapeutic Constructs and Methods of Making and Using

    US20110130616A1